Polaris Partners — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.
BiotechDeep TechHealthtechMedical DevicesAustin, US
Tillman Gerngross(Executive Officer, Director)
Board seatTerrance McGuire· per SEC Form D · $14.5M raise · filed May 2020
Co-investorsGV (Google Ventures)Mithril Capital Management
Philadelphia, US
Gabriel Otte(Executive Officer, Director)
BoardCharles Roberts(Director)
Board seatAmir Nashat· per SEC Form D · $270M raise · filed Aug 2020
Co-investorsAndreessen HorowitzRA Capital
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
Board seatAmir Nashat· per SEC Form D · $24M raise · filed Nov 2020
Co-investorsBioBritBioRock VenturesSamsara BioCapital
Cambridge, MA gene-control biopharma that developed tamibarotene for RARA-overexpressing blood cancers; now in wind-down.
Cambridge, US
Board seatAmir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020
Co-investorsARCH Venture PartnersSamsara BioCapital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.